CN112841575A - Soft edible areca and preparation method thereof - Google Patents
Soft edible areca and preparation method thereof Download PDFInfo
- Publication number
- CN112841575A CN112841575A CN202110170450.5A CN202110170450A CN112841575A CN 112841575 A CN112841575 A CN 112841575A CN 202110170450 A CN202110170450 A CN 202110170450A CN 112841575 A CN112841575 A CN 112841575A
- Authority
- CN
- China
- Prior art keywords
- areca
- alkaloid
- betel nut
- taurine
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 24
- 241000202755 Areca Species 0.000 title abstract 3
- 244000080767 Areca catechu Species 0.000 claims abstract description 152
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 102
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 85
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960003080 taurine Drugs 0.000 claims abstract description 51
- 229930013930 alkaloid Natural products 0.000 claims abstract description 48
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 35
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 claims abstract description 30
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000003513 alkali Substances 0.000 claims abstract description 26
- 229960001948 caffeine Drugs 0.000 claims abstract description 26
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000002791 soaking Methods 0.000 claims abstract description 10
- 235000013353 coffee beverage Nutrition 0.000 claims abstract description 4
- 239000012267 brine Substances 0.000 claims description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 17
- 244000269722 Thea sinensis Species 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 235000003599 food sweetener Nutrition 0.000 claims description 10
- 239000003765 sweetening agent Substances 0.000 claims description 10
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 7
- 239000000920 calcium hydroxide Substances 0.000 claims description 7
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 229940083466 soybean lecithin Drugs 0.000 claims description 7
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 6
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 6
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 235000017550 sodium carbonate Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 5
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 5
- 241001131796 Botaurus stellaris Species 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 4
- 239000003651 drinking water Substances 0.000 claims description 4
- 235000020188 drinking water Nutrition 0.000 claims description 4
- 150000002194 fatty esters Chemical class 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 235000011181 potassium carbonates Nutrition 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 claims description 4
- QSRAJVGDWKFOGU-WBXIDTKBSA-N rebaudioside c Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]1(CC[C@H]2[C@@]3(C)[C@@H]([C@](CCC3)(C)C(=O)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)CC3)C(=C)C[C@]23C1 QSRAJVGDWKFOGU-WBXIDTKBSA-N 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 239000000892 thaumatin Substances 0.000 claims description 4
- 235000010436 thaumatin Nutrition 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 229940074045 glyceryl distearate Drugs 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229920000223 polyglycerol Polymers 0.000 claims description 3
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 3
- 239000013557 residual solvent Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- LTDANPHZAHSOBN-IPIJHGFVSA-N (2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8R,9R,10S,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LTDANPHZAHSOBN-IPIJHGFVSA-N 0.000 claims description 2
- WRPAFPPCKSYACJ-ZBYJYCAASA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8r,9r,10s,11r,13r,14s,17r)-17-[(5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydrox Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H](CCC(C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@@H]3[C@]2(C)CC1)C)C(C)(C)O)[C@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O WRPAFPPCKSYACJ-ZBYJYCAASA-N 0.000 claims description 2
- GHBNZZJYBXQAHG-KUVSNLSMSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GHBNZZJYBXQAHG-KUVSNLSMSA-N 0.000 claims description 2
- XJIPREFALCDWRQ-UYQGGQRHSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-[(3r,6r)-2-hydroxy-6-[(3s,8s,9r,10r,11r,13r,14s,17r)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1h-cyclop Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJIPREFALCDWRQ-UYQGGQRHSA-N 0.000 claims description 2
- KYVIPFHNYCKOMQ-YMRJDYICSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[(3r,6r)-2-hydroxy-6-[(3s,8s,9r,10r,11r,13r,14s,17r)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYVIPFHNYCKOMQ-YMRJDYICSA-N 0.000 claims description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 claims description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 2
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 239000004377 Alitame Substances 0.000 claims description 2
- 239000001329 FEMA 3811 Substances 0.000 claims description 2
- 239000001512 FEMA 4601 Substances 0.000 claims description 2
- 239000001776 FEMA 4720 Substances 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 235000019501 Lemon oil Nutrition 0.000 claims description 2
- KYVIPFHNYCKOMQ-UHFFFAOYSA-N Mogroside III Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O KYVIPFHNYCKOMQ-UHFFFAOYSA-N 0.000 claims description 2
- 108050004114 Monellin Proteins 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- 235000019502 Orange oil Nutrition 0.000 claims description 2
- 101000865553 Pentadiplandra brazzeana Defensin-like protein Proteins 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 claims description 2
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 claims description 2
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 claims description 2
- OMHUCGDTACNQEX-OSHKXICASA-N Steviolbioside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OMHUCGDTACNQEX-OSHKXICASA-N 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 235000019409 alitame Nutrition 0.000 claims description 2
- 108010009985 alitame Proteins 0.000 claims description 2
- 229940064804 betadine Drugs 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- JLPRGBMUVNVSKP-AHUXISJXSA-M chembl2368336 Chemical compound [Na+].O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C([O-])=O)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O JLPRGBMUVNVSKP-AHUXISJXSA-M 0.000 claims description 2
- 108010010165 curculin Proteins 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- CANAPGLEBDTCAF-UHFFFAOYSA-N dulcoside a Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC23C(CC4(C2)C(C2(C)C(C(CCC2)(C)C(=O)OC2C(C(O)C(O)C(CO)O2)O)CC4)CC3)=C)OC(CO)C(O)C1O CANAPGLEBDTCAF-UHFFFAOYSA-N 0.000 claims description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 239000010501 lemon oil Substances 0.000 claims description 2
- 229930191869 mogroside IV Natural products 0.000 claims description 2
- OKGRRPCHOJYNKX-UHFFFAOYSA-N mogroside IV A Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O OKGRRPCHOJYNKX-UHFFFAOYSA-N 0.000 claims description 2
- WRPAFPPCKSYACJ-UHFFFAOYSA-N mogroside IV E Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O WRPAFPPCKSYACJ-UHFFFAOYSA-N 0.000 claims description 2
- TVJXHJAWHUMLLG-UHFFFAOYSA-N mogroside V Natural products CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3O)C(O)C(O)C1O)C(C)(C)O)C4CCC5(C)C6CC=C7C(CCC(OC8OC(COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C8O)C7(C)C)C6(C)C(O)CC45C TVJXHJAWHUMLLG-UHFFFAOYSA-N 0.000 claims description 2
- 235000021096 natural sweeteners Nutrition 0.000 claims description 2
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 claims description 2
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 claims description 2
- 235000010434 neohesperidine DC Nutrition 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 239000010502 orange oil Substances 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 235000019203 rebaudioside A Nutrition 0.000 claims description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 2
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 claims description 2
- QRGRAFPOLJOGRV-UHFFFAOYSA-N rebaudioside F Natural products CC12CCCC(C)(C1CCC34CC(=C)C(CCC23)(C4)OC5OC(CO)C(O)C(OC6OCC(O)C(O)C6O)C5OC7OC(CO)C(O)C(O)C7O)C(=O)OC8OC(CO)C(O)C(O)C8O QRGRAFPOLJOGRV-UHFFFAOYSA-N 0.000 claims description 2
- HYLAUKAHEAUVFE-AVBZULRRSA-N rebaudioside f Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HYLAUKAHEAUVFE-AVBZULRRSA-N 0.000 claims description 2
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- XJIPREFALCDWRQ-UHFFFAOYSA-N siamenoside I Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)OC2C(C(O)C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O XJIPREFALCDWRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940080352 sodium stearoyl lactylate Drugs 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 229940071209 stearoyl lactylate Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- DRSKVOAJKLUMCL-MMUIXFKXSA-N u2n4xkx7hp Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DRSKVOAJKLUMCL-MMUIXFKXSA-N 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- VXTORWLHOHVQAT-UHFFFAOYSA-N calcium;octadecanoyl octadecanoate Chemical compound [Ca].CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC VXTORWLHOHVQAT-UHFFFAOYSA-N 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 5
- 230000000711 cancerogenic effect Effects 0.000 abstract description 4
- 231100000315 carcinogenic Toxicity 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 17
- 235000013616 tea Nutrition 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 240000008154 Piper betle Species 0.000 description 10
- 235000008180 Piper betle Nutrition 0.000 description 10
- 238000010812 external standard method Methods 0.000 description 10
- 235000020688 green tea extract Nutrition 0.000 description 10
- 229940094952 green tea extract Drugs 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 230000007774 longterm Effects 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000005686 eating Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- DNJFTXKSFAMXQF-UHFFFAOYSA-N Arecaidine Chemical compound CN1CCC=C(C(O)=O)C1 DNJFTXKSFAMXQF-UHFFFAOYSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241001126309 Fasciolopsis Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000020733 paullinia cupana extract Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000175 potential carcinogenicity Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a soft edible areca, wherein the mass content of areca alkaloid is lower than 0.01 wt%; the caffeine accounts for 0.01-0.2 wt% of the total weight of the coffee beverage; the taurine accounts for 0.01-0.3 wt% of the total weight of the composition. The transporting material betel nut for the soft edible betel nut is obtained by soaking the betel nut in the alkali liquor containing the surfactant, so that alkaloids including the arecoline are basically removed, the carcinogenic risk and addiction of the common edible betel nut are avoided, the soft edible betel nut is green and healthy, and the commercial value is high.
Description
Technical Field
The invention relates to the field of edible betel nuts, in particular to a soft edible betel nut and a preparation method thereof.
Background
Betel nut, also known as Areca nut, bingmen, olive, young, Areca nut jade, is a mature fruit of betel nut (Areca catechu L.) of the class monocotyledonous plants, order of newborn, family palmaceae, genus Areca, genus evergreen arbor. Betel nuts are native to malaysia and widely cultivated in tropical regions of asia. The planting of Chinese areca is mainly distributed in tropical areas such as Yunnan, Hainan and Taiwan.
Betel nut is an important Chinese medicinal material. Traditionally, betel nut has the efficacy of killing parasites, breaking food retention, descending qi, activating stagnancy, activating water and resolving dampness, and has been used for treating parasitic infections such as tapeworm, hookworm, roundworm, fasciola, fasciolopsis and the like. According to the record of medical science, the main functions of betel nut are as follows: it is indicated for severe diarrhea and dysentery, pain in the heart and abdomen, constipation and constipation, dyspnea with phlegm and dyspnea. Treat malaria, preliminary abdominal distension, take it as powder and induce diuresis. Apply sore, promote granulation and alleviate pain. Burn is grey, manifested as white sore in the mouth, removing wind, eliminating pathogenic qi, activating joints, inducing resuscitation, tonifying five strains and seven impairments, invigorating spleen, regulating middle warmer, relieving restlessness, and breaking mass.
Betel nut contains many natural active ingredients. The researches show that the main active ingredients in the areca-nut include polyphenol, tannin, polysaccharide, fatty acid, crude fiber, alkaloid, anthocyanin, procyanidine, areca-nut red pigment, saponin, amino acid, trace elements and the like. Wherein, various alkaloids in the areca are specific active ingredients of the areca, and the content is about 0.3 to 0.6 percent. The areca-nut alkaloids are mainly arecoline, secondly arecaidine, and in addition demethylarecoline, demethylarecaidine, isodemethylarecaidine, arecanolide and homoarecaine, which are present in combination with tannic acid. The medical community considers that oral ulcer, gingival degeneration and submucosal fibrosis can be caused by frequent chewing of areca nuts, and further oral canceration is caused, medical research finds that the risk of oral canceration is increased by 8.4-9.9 times by chewing of the areca nuts, and arecoline in the areca nuts has potential carcinogenicity. Experiments in the United states and Japan have been conducted with extracts of Areca catechu, which have been found to cause murine carcinogenesis. Areca catechu has been found in the medical community to be significantly associated with pharyngeal cancer, laryngeal cancer, esophageal cancer, etc. World health organization international agency for research on cancer carcinogens list class 1 carcinogens. However, at present, the national standard of edible betel nuts is not issued by the country, and the content of the betel nut alkaloid is limited; the local standard of edible areca in Taiwan of Hunan province does not have the related quality index of arecoline.
In addition, arecoline in areca is also a substance with addiction to areca, can stimulate nerves of a chewer to generate excitement and can also enhance the tolerance of the nerves, namely, the chewer is less and less sensitive to the substance, so that the addiction is laid, and long-term use of the areca can lead the eater to have stronger dependence type, which is the same as the reason of a smoker.
Therefore, the development of edible areca nuts containing no arecoline or low arecoline content is an effective solution for reducing the potential safety hazard caused by long-term consumption of areca nuts at present.
Disclosure of Invention
Aiming at solving the problem that the areca-nut food prepared in the prior art contains arecoline, and has potential safety and health hazards after long-term use; meanwhile, aiming at the defects of the existing marinating process, the invention aims to provide edible areca nuts with low alkaloid or no alkaloid, wherein the edible areca nuts contain no or very little areca nut alkaloid, but also have the effects of refreshing, restoring consciousness, exciting nerves, relieving fatigue, pleasantly body and mind and the like, and are free from addiction.
The softening of the soft edible betel nut and the common edible betel nut is not the same concept, and the common softened betel nut adopts a physical and chemical means to soften betel nut fiber and improve the mouthfeel; the term "soft" as used herein means that the betel nut is not harmful or addictive to the consumer compared to the conventional betel nut.
The invention provides a soft edible areca, wherein the mass content of areca alkaloid is lower than 0.01 wt%; the caffeine accounts for 0.01-0.2 wt% of the total weight of the coffee beverage; the taurine accounts for 0.01-0.3 wt% of the total weight of the composition.
Furthermore, in the edible betel nut, the content of the betel nut alkaloid is lower than 0.005 wt%; the caffeine accounts for 0.05-0.12 wt% of the total weight of the beverage; the taurine accounts for 0.1-0.2 wt% of the total weight of the composition.
In the present invention, the caffeine is derived from natural extracts such as tea extracts (green tea extract, black tea extract), coffee bean extract, cacao extract, guarana extract; the taurine is extracted from natural animals and plants, biologically fermented or organically synthesized.
The invention also provides the soft edible areca and a preparation method thereof, and the preparation method comprises the following steps:
(1) taking areca nuts without alkaloid or low alkaloid as raw materials, and cleaning;
(2) fermenting, baking, perfuming the surface, cutting fruit and removing kernel;
(3) pointing and condensing bittern;
(4) packaging to obtain the finished product.
In the step (1), the areca nuts without alkaloid or low alkaloid are obtained by a physical/chemical method, and the content of the arecoline in the treated areca nuts is below 0.01 wt%, preferably below 0.005 wt%.
Preferably, the preparation method of the betel nut without alkaloid or low alkaloid refers to the prior patent application CN202110140884.0 of the applicant, specifically, the betel nut raw material is obtained by soaking in an alkaline solution containing a surfactant, and the betel nut serving as the raw material is fresh betel nut, dry betel nut (olive or smoked fruit) or sliced betel nut.
The alkali liquor is aqueous solution of sodium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate, and the pH of the alkali liquor is 11-13. When the alkali is sodium hydroxide or potassium hydroxide, the concentration of the alkali liquor is 0.1-0.3 wt%, and when the alkali is sodium carbonate, potassium carbonate, sodium bicarbonate or potassium bicarbonate, the mass concentration of the alkali liquor is 4-10 wt%. The volume consumption of the alkali liquor is 3-10 times (L/kg) of the weight of the areca nut raw material.
The concentration of the surfactant in the alkali liquor is 0.1-0.5g/L, preferably 0.15-0.2 g/L.
The surfactant is food-grade surfactant, including but not limited to lecithin, soybean phospholipid, glycerol monostearate, glycerol distearate, sucrose fatty acid ester, calcium stearoyl lactylate, polyglycerol fatty ester, and sucrose glycerol fatty acid ester. Preferably phosphorus ester surfactants (lecithin, soybean lecithin) and fatty acid surfactants (glycerol monostearate, glycerol distearate, sucrose fatty acid ester, calcium stearoyl lactylate, polyglycerol fatty ester and sucrose glycerol fatty acid ester) according to the mass ratio of 3-5: 1; more preferably, the soybean lecithin and the glycerol distearate are compounded according to the mass ratio of 3-5: 1.
The areca-nut without alkaloid or with low alkaloid used in the invention is obtained by the preparation method comprising the following steps:
(S1) selecting fruits: selecting fresh or dry betel nut fruits as raw materials;
(S2) soaking in alkali liquor: soaking the areca nuts in the step (1) in alkaline liquor containing a surfactant;
(S3) cleaning: taking out the areca nuts in the step (2) from the alkali liquor, washing the areca nuts to be neutral, and drying the areca nuts;
(S4) extracting: extracting the areca nuts drained in the step (3) by using a mixed solvent, filtering to remove the solvent, then distilling the residual solvent in the areca nuts by using water vapor, and drying to obtain the alkaloid-free/low-alkaloid areca nuts.
In the step (S2), the soaking time is 24 to 48 hours.
In the step (S4), the mixed solvent is a mixed solvent of one or more solvents of 6# solvent oil, 120# solvent oil, petroleum ether, diethyl ether, cyclohexane, n-hexane or heptane and ethyl acetate; the dosage of the mixed solvent is 5-20 times (L/kg), preferably 10-16 times (L/kg) of the weight of the areca nut raw material. Further, the volume ratio of at least one of No. 6 solvent oil, No. 120 solvent oil, petroleum ether, diethyl ether, cyclohexane, n-hexane and heptane to ethyl acetate is 5-15: 1, preferably 7 to 9: 1.
in the step (2), the fermentation, the baking, the skin perfuming, the fruit cutting and the kernel removing are conventional processes in the preparation process of the betel nut food, and the used fermentation liquid and the fragrance sealing liquid are common liquid medicines which are not specifically explained and can be obtained by commercially available materials and preparation. For example, in the specific embodiment of the present invention, the fermentation solution is water, food-grade sodium carbonate and food-grade sodium bicarbonate in a mass ratio of 100: 40: 55.
Marinating is a key process in the process of processing areca nuts. The Arecae semen bittern is slurry obtained by heating and reacting sweet substances such as calcium hydroxide and maltose, and is added with sweetener and perfume to improve Arecae semen taste. The areca contains tannin, so the inner surface of areca is strongly acidic, therefore, lime is added into the traditional areca brine to neutralize the acidity, and simultaneously sweetener such as maltose and flavoring agent are added to correct the taste. After lime brine is poured into the inner surface of the semi-finished betel nut product, alkaline substances in the brine permeate into the inner fiber layer through the inner surface of the betel nut, so that the acidity of the betel nut is reduced.
Preferably, in the step (3), the brine used for the bittern spotting contains the tea extract and taurine in addition to the ingredients such as common drinking water, slaked lime, sweetening agent and the like.
Preferably, the brine used for brine pointing comprises the following raw materials in percentage by mass: 10-20 wt% of food-grade calcium hydroxide, 20-60 wt% of maltose, 5-10 wt% of tea extract, 1-2 wt% of taurine and the balance of drinking water.
In a preferred technical scheme of the invention, other auxiliary materials can be added into the brine formula according to requirements, and the components and the dosage of the auxiliary materials are known in the art, such as 1-3 wt% of emulsifier, 1-3 wt% of water-retaining agent, 0.5-2 wt% of gel, 0.1-5 wt% of sweetener and 0.1-2 wt% of essence.
The emulsifier, water retention agent, gelling agent, sweetener are well known in the art and are not particularly limited. For example, the emulsifier is typically a fatty acid or stearoyl lactylate such as sucrose fatty acid ester, glycerol monostearate, calcium stearoyl lactylate, sodium stearoyl lactylate; the water-retaining agent is at least one of lactitol and polydextrose; the gel is sodium alginate, carrageenan and xanthan gum; the sweetener comprises a natural sweetener, such as at least one of mogroside V, 11-O-mogroside V, mogroside VI, siamenoside I, mogroside IV, mogroside III, stevioside, rebaudioside a, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside a, rubusoside, steviolbioside, glycyrrhizin, maltose, Thaumatin (Thaumatin), monellin, mabinlin, curculin, betadine (Pentadin), and Brazzein; or a synthetic sweetener such as at least one of sucralose, aspartame, alitame, sodium saccharin, neotame, acesulfame k, cyclamate, and neohesperidin dihydrochalcone; the essence comprises natural plant essences such as menthol, orange oil and lemon oil.
Taurine is an amino acid essential to humans and animals. Taurine can strengthen physique, eliminate fatigue, raise daily work efficiency, prevent diseases, etc. The lack of taurine in the body of children can cause dysplasia, vision damage, increased susceptibility to epilepsy and even cardiomyopathy and other diseases; the lack of taurine in adults also endangers their health. Taurine has no side effect on human body because taurine is synthesized by human body itself, but the amount of taurine synthesized is small and is changed according to the amount of taurine contained in food eaten by human body every day. In the case of lacking taurine, the human body needs to be supplemented with additional taurine, because the lack of taurine in the human body can have great adverse effects on human brain, eyes, nerves and the like.
Taurine is widely used as an excellent food additive in developed countries such as europe, the united states and japan. In countries such as the United states and the Japan, the taurine accounting for 99 percent of the total dosage is used as a food additive. For example: in order to ensure the healthy growth of infants in countries such as America and Japan, the content of taurine in infant dairy products is clearly specified and is not less than 0.16mg/100mL, especially, Japan has mandatory requirements, taurine must be added into children food, otherwise, the children food is not allowed to be sold on the market; taurine is also added to beverages, complex monosodium glutamate, soy products, dairy products, and nutraceuticals in japan. Until 1990, taurine was not allowed to be added as a nutritional food additive to dairy products, beverages and complex condiments and its use limit was clearly required. Research shows that the nutritive value of the milk powder can approach to that of breast milk by adding a proper amount of taurine into the milk and the milk powder. Taurine can also be used as a high-quality additive for foods and beverages for pilots, astronauts, athletes, etc., to enhance physical fitness and relieve fatigue. In the future, taurine is expected to be mainly used as a food nutrition additive, and the application of the taurine in the aspect of food additives is expected to be more extensive.
The tea extract is an active component extracted from tea leaves, and mainly comprises tea polyphenol (catechin), alkaloid (mainly caffeine), aromatic oil, minerals, pigments, polysaccharides, proteins, amino acids (theanine), vitamins and the like. The research finds that the tea polyphenol has the capability of eliminating active oxygen free radicals, lipid free radicals and aromatic hydrocarbon free radicals, and various polyphenol components have synergistic action. Due to the existence of a large amount of tea polyphenol, the tea extract has the following biological activity: antioxidant, mutation resisting, antibacterial, blood pressure lowering, blood lipid reducing, blood sugar lowering, dental caries preventing, immunity improving, diuresis promoting, antiinflammatory, physiological regulating, etc. Caffeine is an important active ingredient in tea extracts. Caffeine, a xanthine alkaloid compound, is a central nervous stimulant that temporarily drives drowsiness and restores energy, and is used clinically to treat neurasthenia and coma resuscitation. Coffee, tea, soft drinks and energy drinks with caffeine content are well marketed and therefore caffeine is also the most commonly used psychotropic drug in the world.
The beneficial effects of caffeine include: prevent the brain from receiving adenylate, thereby keeping the brain awake, helping to concentrate attention and reduce fatigue; the dementia can be prevented by taking appropriate amount of caffeine regularly; the muscle vitality and durability are enhanced, the physical strength and the perseverance are enhanced, and the training time and the training effect are greatly improved; promoting metabolism; the efficacy of antioxidant phenolic substances can be doubled; preventing skin cancer, breast cancer and diabetes.
However, excessive caffeine intake is undesirable, and adverse side effects such as gastrointestinal discomfort, mental confusion, anxiety, depression, anxiety, restlessness, increased blood pressure, and increased epinephrine levels may occur in other patients. According to the European food safety scientific research, the daily safe caffeine intake of an adult is 400mg, and the amount of each intake cannot exceed 200 mg.
According to the invention, in the brine process, the tea extract and the taurine in a proper proportion are creatively compounded and then added into the conventional brine formula, so that the defects of the decline of the functions of refreshing, restoring consciousness, relieving fatigue and resisting fatigue after the alkaloid of the betel nut is removed can be overcome, the mouthfeel of the betel nut can be improved to a certain extent, and the trend of the taste decline caused by the removal of the alkaloid is reduced.
The method has the following beneficial effects:
(1) the method provides a novel soft edible areca, which does not contain alkaloid or has low alkaloid content, so that the method does not cause carcinogenic hidden trouble caused by the alkaloid of the areca and does not cause addiction, and the areca can be eaten at ease.
(2) Although no alkaloid (or low alkaloid) exists in the soft edible betel nut, a certain amount of tea extract and taurine are added in the brine for compounding, the effects of refreshing brain, exciting nerves, relieving fatigue, pleasuring body and mind and the like are achieved, addiction is avoided, the prepared soft edible betel nut has good taste and flavor, the market acceptance degree is good, and the unique taste and flavor of the betel nut cannot be lost due to the deficiency of betel nut alkaloid.
Detailed Description
The present invention will be further described with reference to the following examples.
In the examples of the present invention, "%" represents mass%, and "parts" represent parts by mass, if specifically indicated.
The raw material of the areca nut without alkaloid or low alkaloid used in the embodiment of the invention is from Hunan China Cheng biological resources GmbH; the green tea extract used in the embodiment of the invention is from Hunan China Cheng biological resource GmbH, the content of tea polyphenol is 42.5%, and the content of caffeine is 4.1%; taurine is purchased from Zhengzhou spring and autumn chemical Co., Ltd., and has a purity of more than 99.6%.
Other adjuvants used in the examples of the present invention, unless otherwise specified, are commercially available in a conventional manner.
The HPLC sample is prepared by pulverizing edible Arecae semen, ultrasonic extracting with 50 weight times of methanol, centrifuging, collecting supernatant, and testing. HPLC Agilent100 HPLC, mobile phase methanol: water 6: 4.
Preparation example 1
(1) Selecting fruits: selecting 50kg of dry areca nuts without rot, disease spots and insect pests as raw materials, slicing and removing kernels;
(2) soaking in alkali liquor: soaking betel nuts in 300L of alkali liquor, wherein the alkali liquor is a sodium carbonate aqueous solution with the mass percentage concentration of 6%, and the alkali liquor contains 50g of lecithin for 24 hours;
(3) cleaning: taking out the areca from the alkali liquor, rinsing the areca to be neutral by using pure water, and draining or drying the areca;
(4) mixed solvent extraction: and (3) extracting the areca nuts with water drained in the step (3) twice by refluxing with a mixed solvent (6# solvent oil: ethyl acetate: 9: 1, V/V). The dosage of the mixed solvent for the first reflux extraction is 800L, and the reflux extraction time is 4 hours; the dosage of the mixed solvent for the second reflux extraction is 600L, and the reflux extraction time is 3 hours. After the reflux extraction is finished, filtering to remove the solvent, distilling the residual solvent in the betel nut by using water vapor, and drying to obtain the low-alkaloid betel nut.
Preparation example 2
The other conditions were the same as in preparation example 1 except that lecithin was replaced with soybean lecithin of the same quality in step (2).
Preparation example 3
The other conditions were the same as in preparation example 1 except that in step (2), 37.5g of soybean lecithin and 12.5g of glyceryl distearate were contained in 300L of an alkali solution.
Preparation example 4
The other conditions were the same as in preparation example 1 except that in step (2), 37.5g of soybean lecithin and 12.5g of glyceryl distearate were contained in 300L of an alkali solution.
Preparation example 5
The other conditions were the same as in preparation example 1 except that in step (2), 41.5g of lecithin and 8.5g of glycerol distearate were contained in 300L of a basic solution.
Example 1
(1) Taking the areca-nut without alkaloid obtained in the preparation example 1 as a raw material, and cleaning;
(2) adding cleaned Arecae semen into a fermentation tank, fermenting at 35 deg.C under 0.4MPa for 48 hr to obtain fermented product; baking at 45 deg.C for 1 hr, adding into a sealed jar, and sealing at 35 deg.C for 10 hr; slicing the betel nut with a slicer, and removing the core;
(3) the formula of the brine comprises 13 wt% of food-grade calcium hydroxide, 42 wt% of maltose, 6.2 wt% of green tea extract, 1.6 wt% of taurine, 1.3 wt% of sucrose fatty acid ester, 0.8 wt% of calcium stearoyl lactylate, 1.4 wt% of lactitol, 2.1 wt% of sodium alginate, 0.05 wt% of aspartame, 2.5 wt% of sucrose, 1.6 wt% of menthol and the balance of drinking water, and after the brine is prepared, the areca nuts sliced and denucleated in the step (2) are marinated and condensed;
(4) packaging to obtain soft edible Arecae semen product.
The content of total alkaloids in the soft edible areca finished product obtained in the embodiment is 0.0049% by detection of a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.08%; the taurine content is 0.15%.
Example 2
The other steps and conditions were the same as in example 1 except that the starting material used in step (1) was areca catechu obtained in preparation example 2.
The content of total alkaloids in the soft edible areca finished product obtained in the embodiment is 0.0069% detected by a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.07%; the taurine content is 0.15%.
Example 3
The other steps and conditions were the same as in example 1 except that the starting material used in step (1) was areca catechu obtained in preparation example 3.
The total alkaloids are not detected in the soft edible areca finished product obtained in the embodiment by a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.08%; the taurine content is 0.16%.
Example 4
The other steps and conditions were the same as in example 1 except that the starting material used in step (1) was areca catechu obtained in preparation example 4.
The content of total alkaloids in the soft edible areca finished product obtained in the embodiment is 0.0018% detected by a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.09%; the taurine content is 0.16%.
Example 5
The other steps and conditions were the same as in example 1 except that the starting material used in step (1) was areca catechu obtained in preparation example 5.
The content of total alkaloids in the soft edible areca finished product obtained in the embodiment is 0.0014% detected by a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.09%; the taurine content is 0.15%.
Example 6
The other steps and conditions were the same as in example 1 except that in the brine formulation in step (2), green tea extract was 5 wt% and taurine was 2 wt%. The total alkaloids are not detected in the soft edible areca finished product obtained in the embodiment by a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.05%; the taurine content was 0.19%.
Example 7
The other steps and conditions were the same as in example 1 except that in the brine formulation in step (2), 10 wt% of green tea extract and 1 wt% of taurine were used. The total alkaloids are not detected in the soft edible areca finished product obtained in the embodiment by a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.12%; the taurine content was 0.11%.
Example 8
The other steps and conditions were the same as in example 1 except that in the brine formulation in step (2), green tea extract was 7.5 wt% and taurine was 1.4 wt%. The total alkaloids are not detected in the soft edible areca finished product obtained in the embodiment by a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.10%; the taurine content is 0.15%.
Comparative example 1
The other steps and conditions were the same as in example 1 except that in the step (3) of marinating, the green tea extract was not added. Through detection by a High Performance Liquid Chromatography (HPLC) external standard method, no total alkaloids are detected in the soft edible areca finished product obtained in the embodiment; the taurine content is 0.16%.
Comparative example 2
The other steps and conditions were the same as in example 1 except that taurine was not added in the step (3) of dehalogenation. The total alkaloids are not detected in the soft edible areca finished product obtained in the embodiment by the detection of a High Performance Liquid Chromatography (HPLC) external standard method; the content of caffeine is 0.08%.
Application example 1 taste testing
110 male subjects with eating habits of betel nuts are selected, 10 subjects are taken as 1 group, the betel nuts are eaten according to the examples, the proportion and the commercial finished products, 10 subjects in each group are scored according to the taste and the chewiness, and the score is further scored after eating for one month (3 times a day and one time). Each test item was rated 5 full, indicating the most satisfactory consumer, and rated 1 minimum. The comparison example is that a certain brand of edible betel nut is directly purchased in the market. The specific scoring criteria are shown in table 1 below:
TABLE 1
Scoring | Taste of the product |
5 points of | Has good taste |
4 is divided into | Has good taste |
3 points of | Has a general taste |
2 is divided into | Has poor taste |
1 minute (1) | Has poor taste |
After one month of betel nut administration to each group of subjects, the subjects were scored according to the above criteria and averaged, and the results are shown in table 2 below:
TABLE 2
As can be seen from the data in Table 2, the soft betel nuts used in the embodiment of the invention are treated to contain almost no arecoline, so that the carcinogenic risk and addiction caused by the arecoline are greatly avoided or reduced, and the stomach and the oral cavity of the subject are obviously relieved after the subject eats the soft betel nuts for one month. We have found that although the initial eating score of the soft betel nut of the present invention is not high in terms of taste and flavor for the first time in the case of long-term betel nut consumption, most of the subjects slowly received the soft betel nut with alkaloid removed after one month of consumption, and the taste and flavor score was increased. The soft betel nut provided by the invention is fully demonstrated, so that the taste and flavor of the betel nut are not obviously changed when the addiction to betel nut use can be greatly reduced, and the betel nut can be accepted by people with long-term eating habits of the betel nut. By comparing the examples with the comparative examples, the green tea extract and taurine in the brine formulation, if one of them is missing, have little effect on the initial mouthfeel, but the taste of the mouthfeel is not enhanced significantly after the test subject eats for one month. The results show that the synergistic cooperation effect of the taurine and the green tea extract plays an important role in adapting to new soft betel nuts for long-term betel nut eaters, and the absence of any one of the taurine and the green tea extract can not effectively enable the long-term betel nut eaters to change the habit of eating the betel nuts without alkaloid/with low alkaloid, thereby affecting the market acceptance degree.
Application example 2 Refreshment test
The test subjects were adult men aged 30-35 years old, and in order to avoid the data of dependent subjects from influencing the results, the subjects had no betel nut eating habit before. Subjects were self-assessed for drowsiness and wakefulness using a wakefulness scale. The classification is carried out on 5 grades from 1 to 5, wherein 1 represents the lowest degree, and represents that the people are cachectic and do not concentrate on the mind; 5 indicates that the degree is highest, the patient is clear-headed, can concentrate attention and is not sleepy; 60 subjects were randomized into 6 groups of 10. The control group eats a certain brand of edible betel nut directly purchased in the market. Sleepiness/wakefulness measurements were taken 5 days before the experiment, and the mean value was compared to the post-experiment control. The test method comprises the steps of eating the areca nuts three times a day, one betel nut each time, testing after half an hour after the areca nuts are eaten, continuously performing the test for 10 days, wherein during the whole test period, the work and rest time and the work intensity of a subject each day have no obvious change, and meanwhile, the areca nuts are not eaten and used (including essential oil, spray, chewing gum with the function of refreshing, perfume, shampoo and the like) any substance with the function of refreshing, or food, medicine, beverage and the like.
The results of the arousal test are shown in table 3 below:
TABLE 3
Indicates that the degree of wakefulness of the subjects was significantly different after and before the experiment (P <0.05)
The tests show that the soft edible areca and the commercial areca purchased conventionally in the market have obvious effects of reminding a subject of consciousness and restoring consciousness, and the method adopts the raw materials without arecoline or low arecoline, but has obvious effects of refreshing the mind and restoring consciousness due to the addition of caffeine and taurine, can avoid carcinogenic risks and addiction to a human body caused by the arecoline, is a green and healthy novel soft edible areca and has great commercial value.
Claims (10)
1. A soft edible Arecae semen contains Arecae semen alkaloid less than 0.01 wt%; the caffeine accounts for 0.01-0.2 wt% of the total weight of the coffee beverage; the taurine accounts for 0.01-0.3 wt% of the total weight of the composition.
2. The edible, supple areca nut of claim 1, wherein the areca alkaloid content is less than 0.005 wt%; the caffeine accounts for 0.05-0.12 wt% of the total weight of the beverage; the taurine accounts for 0.1-0.2 wt% of the total weight of the composition.
3. The method for preparing the soft edible betel nut as claimed in claim 1 or 2, comprising the steps of:
(1) taking areca nuts without alkaloid or low alkaloid as raw materials, and cleaning;
(2) fermenting, baking, perfuming the surface, cutting fruit and removing kernel;
(3) pointing and condensing bittern;
(4) packaging to obtain the finished product.
4. The method according to claim 3, wherein in step (1), the alkaloid-free or low-alkaloid betel nut is obtained by physically/chemically treating betel nut, and the treated betel nut contains arecoline in an amount of less than 0.01 wt%, preferably less than 0.005 wt%.
5. The method of claim 3, wherein the alkaloid-free or low-alkaloid betel nut is prepared by soaking betel nut in an alkaline solution containing a surfactant.
6. The method of claim 5, wherein the alkaline solution is an aqueous solution of sodium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and the pH of the alkaline solution is 11-13. When the alkali is sodium hydroxide or potassium hydroxide, the concentration of the alkali liquor is 0.1-0.3 wt%, and when the alkali is sodium carbonate, potassium carbonate, sodium bicarbonate or potassium bicarbonate, the mass concentration of the alkali liquor is 4-10 wt%. The volume consumption of the alkali liquor is 3-10 times (L/kg) of the weight of the areca nut raw material; the concentration of the surfactant in the alkali liquor is 0.1-0.5g/L, preferably 0.15-0.2 g/L.
7. The method of claim 5, wherein the surfactant is a food grade surfactant including but not limited to lecithin, soy lecithin, glyceryl monostearate, glyceryl distearate, sucrose fatty acid ester, calcium stearoyl lactylate, polyglyceryl fatty esters, sucrose glycerin fatty acid ester. Preferably phosphorus ester surfactants (lecithin, soybean lecithin) and fatty acid surfactants (glycerol monostearate, glycerol distearate, sucrose fatty acid ester, calcium stearoyl stearate, polyglycerol fatty ester and sucrose glycerol fatty acid ester) according to the mass ratio of 3-5: 1; more preferably, the soybean lecithin and the glycerol distearate are compounded according to the mass ratio of 3-5: 1.
8. The method of any one of claims 5-7, wherein the alkaloid-free or low-alkaloid areca catechu is obtained by a method comprising the steps of:
(S1) selecting fruits: selecting fresh or dry betel nut fruits as raw materials;
(S2) soaking in alkali liquor: soaking the areca nuts in the step (1) in alkaline liquor containing a surfactant;
(S3) cleaning: taking out the areca nuts in the step (2) from the alkali liquor, washing the areca nuts to be neutral, and drying the areca nuts;
(S4) extracting: extracting the areca nuts drained in the step (3) by using a mixed solvent, filtering to remove the solvent, then distilling the residual solvent in the areca nuts by using water vapor, and drying to obtain the alkaloid-free/low-alkaloid areca nuts.
9. The preparation method according to claim 3, wherein in the step (3), the brine used for the brine nodding comprises the following raw materials in mass content: 10-20 wt% of food-grade calcium hydroxide, 20-60 wt% of maltose, 5-10 wt% of tea extract, 1-2 wt% of taurine and the balance of drinking water.
10. The method of claim 9, wherein the brine formulation further comprises 1-3 wt% of an emulsifier, 1-3 wt% of a water retaining agent, 0.5-2 wt% of a gelling agent, 0.1-5 wt% of a sweetener, and 0.1-2 wt% of a flavor;
preferably, the emulsifier is typically a fatty acid or stearoyl lactylate, such as sucrose fatty acid ester, glycerol monostearate, calcium stearoyl lactylate, sodium stearoyl lactylate; the water-retaining agent is at least one of lactitol and polydextrose; the gelling agent is sodium alginate, carrageenan and xanthan gum; the sweetener comprises a natural sweetener, such as at least one of mogroside V, 11-O-mogroside V, mogroside VI, siamenoside I, mogroside IV, mogroside III, stevioside, rebaudioside a, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside a, rubusoside, steviolbioside, glycyrrhizin, maltose, Thaumatin (Thaumatin), monellin, mabinlin, curculin, betadine (Pentadin), and Brazzein; or a synthetic sweetener such as at least one of sucralose, aspartame, alitame, sodium saccharin, neotame, acesulfame k, cyclamate, and neohesperidin dihydrochalcone; the essence comprises at least one of menthol, orange oil and lemon oil.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110170450.5A CN112841575A (en) | 2021-02-08 | 2021-02-08 | Soft edible areca and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110170450.5A CN112841575A (en) | 2021-02-08 | 2021-02-08 | Soft edible areca and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112841575A true CN112841575A (en) | 2021-05-28 |
Family
ID=75989042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110170450.5A Pending CN112841575A (en) | 2021-02-08 | 2021-02-08 | Soft edible areca and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112841575A (en) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060134300A1 (en) * | 2004-12-20 | 2006-06-22 | Newman Arnold L | Nutritional supplement for caffeine-containing beverages |
US20070031568A1 (en) * | 2005-08-12 | 2007-02-08 | Gardiner Paul T | Supplemental dietary composition including caffeine, taurine and ginseng |
CN101658274A (en) * | 2008-08-30 | 2010-03-03 | 张海德 | Processing method of green betel-nut dry fruit with low arecoline content |
CN104397617A (en) * | 2014-11-24 | 2015-03-11 | 华中农业大学 | Preparation method of areca catechu leisure food |
CN104814405A (en) * | 2015-05-13 | 2015-08-05 | 琼州学院 | Pungent functional areca-nut food and preparation method thereof |
CN106805131A (en) * | 2016-12-31 | 2017-06-09 | 浙江青莲食品股份有限公司 | A kind of processing method of tea perfume Tung-Po meat |
CN108740878A (en) * | 2018-06-28 | 2018-11-06 | 陈辉 | One kind is refreshed oneself slim betel nut and its manufacture craft |
CN108936386A (en) * | 2018-06-21 | 2018-12-07 | 武汉工程大学 | A kind of coffee tea egg preparation method |
CN109674014A (en) * | 2019-01-31 | 2019-04-26 | 方超 | Composition and production method for jasmine tea halogen |
CN110521976A (en) * | 2019-10-16 | 2019-12-03 | 湖南中医药大学 | Areca nut food and preparation method thereof |
CN110897113A (en) * | 2019-10-28 | 2020-03-24 | 湖南天大生物科技股份有限公司 | Preparation method of polygonatum odoratum betel nuts |
CN111034958A (en) * | 2019-12-23 | 2020-04-21 | 湖南宾之郎食品科技有限公司 | Preparation process of areca nuts without wound and free alkali in brine |
CN112120187A (en) * | 2020-09-21 | 2020-12-25 | 湖南胖哥食品有限责任公司 | Preparation method of cistanche betel nut |
-
2021
- 2021-02-08 CN CN202110170450.5A patent/CN112841575A/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060134300A1 (en) * | 2004-12-20 | 2006-06-22 | Newman Arnold L | Nutritional supplement for caffeine-containing beverages |
US20070031568A1 (en) * | 2005-08-12 | 2007-02-08 | Gardiner Paul T | Supplemental dietary composition including caffeine, taurine and ginseng |
CN101658274A (en) * | 2008-08-30 | 2010-03-03 | 张海德 | Processing method of green betel-nut dry fruit with low arecoline content |
CN104397617A (en) * | 2014-11-24 | 2015-03-11 | 华中农业大学 | Preparation method of areca catechu leisure food |
CN104814405A (en) * | 2015-05-13 | 2015-08-05 | 琼州学院 | Pungent functional areca-nut food and preparation method thereof |
CN106805131A (en) * | 2016-12-31 | 2017-06-09 | 浙江青莲食品股份有限公司 | A kind of processing method of tea perfume Tung-Po meat |
CN108936386A (en) * | 2018-06-21 | 2018-12-07 | 武汉工程大学 | A kind of coffee tea egg preparation method |
CN108740878A (en) * | 2018-06-28 | 2018-11-06 | 陈辉 | One kind is refreshed oneself slim betel nut and its manufacture craft |
CN109674014A (en) * | 2019-01-31 | 2019-04-26 | 方超 | Composition and production method for jasmine tea halogen |
CN110521976A (en) * | 2019-10-16 | 2019-12-03 | 湖南中医药大学 | Areca nut food and preparation method thereof |
CN110897113A (en) * | 2019-10-28 | 2020-03-24 | 湖南天大生物科技股份有限公司 | Preparation method of polygonatum odoratum betel nuts |
CN111034958A (en) * | 2019-12-23 | 2020-04-21 | 湖南宾之郎食品科技有限公司 | Preparation process of areca nuts without wound and free alkali in brine |
CN112120187A (en) * | 2020-09-21 | 2020-12-25 | 湖南胖哥食品有限责任公司 | Preparation method of cistanche betel nut |
Non-Patent Citations (6)
Title |
---|
严聃,李彦: "食用槟榔的加工工艺研究", 食品与机械, no. 06, pages 32 - 33 * |
文开齐;: "高效液相色谱/质谱联用法测定槟榔食品中槟榔碱的含量", 中国实用医药, no. 08, pages 369 - 370 * |
李陆军等: "表面活性剂在植物活性成分提取中的应用", 日用化学工业, vol. 49, no. 11, pages 748 - 752 * |
毛春芹;陆兔林;季德;周渊;胡俊扬;王莺;蔡宝昌;: "高效液相色谱法测定不同产地大腹皮中槟榔碱的含量", 中国药学杂志, no. 11, pages 75 - 77 * |
王海灿;吉建邦;康效宁;万祝宁;: "鲜槟榔中槟榔碱的提取工艺研究", 食品与机械, no. 03, pages 60 - 63 * |
胡四琴;徐仿周;高文平;袁劲松;: "槟榔生物碱提取分离及检测方法的研究进展", 中药材, no. 02, pages 146 - 149 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009145363A1 (en) | Composition comprising a hot water extract of hemerocallis plants, said composition being effective in treating fatigue by having antidepressant properties or by improving sleep | |
CN103637331A (en) | Okra juice drink and preparation method therefor | |
JP6100692B2 (en) | Sleep quality improver | |
CN103387899B (en) | Black tea wine and production method thereof | |
CN107535790A (en) | A kind of west safflower ginseng granules drink, its preparation method and application | |
CN107279446A (en) | A kind of betel nut colloid chews piece | |
CN101238909B (en) | Chickpea bean sprout juice and preparation method and application | |
CN102894435B (en) | Mulberry-medlar leaf beverage with function of asthenopia relieving | |
KR101524373B1 (en) | Beverage Composition for Treating Hangover | |
CN112841575A (en) | Soft edible areca and preparation method thereof | |
CN103859520B (en) | Contribute to acanthopanax fruit oral liquid and the preparation method of improving water flood function | |
KR20150010487A (en) | Method of preparing vegetable beverage | |
US20210338761A1 (en) | Composition for preventing, ameliorating, or treating sleep disturbance comprising extract of fraxinus sp. plant as effective component | |
CN113180211B (en) | Soft edible areca added with compound sweetener | |
KR100930910B1 (en) | Beverage containing fresh Schisandra chinensis liquid and its manufacturing method | |
US20220061360A1 (en) | Health functional beverage | |
CN106616099A (en) | Health-care beverage capable of improving appetite of children and preparation method thereof | |
CN105380267B (en) | A kind of functional food and preparation method thereof | |
KR20210115691A (en) | Composition for removing Hangover and health functional food comprising the same | |
KR101572580B1 (en) | Herbal medicine composition having improved adaptability of taking medicine and preparation method thereof | |
KR102671658B1 (en) | Dietary fiber composition for promoting defecation and improving cholesterol containing psyllium hull and manufacturing method thereof | |
KR102717952B1 (en) | Composition for preventing or improving sleep disorder comprising lettuce extract, and method for producing candy using the same | |
CN116918919A (en) | Yellow Pi Suancheng composite beverage and preparation method thereof | |
KR20240092706A (en) | Composition for promoting and improving sleep for solid food and jelly, and manufacturing method thereof | |
CN115581271A (en) | A probiotic beverage containing radix Pseudostellariae and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210528 |